Novel therapeutic agents for cutaneous T-Cell lymphoma

Mycosis fungoides (MF) and Sezary Syndrome (SS) represent the most common subtypes of primary Cutaneous T-cell lymphoma (CTCL). Patients with advanced MF and SS have a poor prognosis leading to an interest in the development of new therapies with targeted mechanisms of action and acceptable safety p...

Descripción completa

Detalles Bibliográficos
Autores principales: Jain, Salvia, Zain, Jasmine, O’Connor, Owen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3418166/
https://www.ncbi.nlm.nih.gov/pubmed/22594538
http://dx.doi.org/10.1186/1756-8722-5-24
_version_ 1782240600650678272
author Jain, Salvia
Zain, Jasmine
O’Connor, Owen
author_facet Jain, Salvia
Zain, Jasmine
O’Connor, Owen
author_sort Jain, Salvia
collection PubMed
description Mycosis fungoides (MF) and Sezary Syndrome (SS) represent the most common subtypes of primary Cutaneous T-cell lymphoma (CTCL). Patients with advanced MF and SS have a poor prognosis leading to an interest in the development of new therapies with targeted mechanisms of action and acceptable safety profiles. In this review we focus on such novel strategies that have changed the treatment paradigm of this rare malignancy.
format Online
Article
Text
id pubmed-3418166
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34181662012-08-14 Novel therapeutic agents for cutaneous T-Cell lymphoma Jain, Salvia Zain, Jasmine O’Connor, Owen J Hematol Oncol Review Mycosis fungoides (MF) and Sezary Syndrome (SS) represent the most common subtypes of primary Cutaneous T-cell lymphoma (CTCL). Patients with advanced MF and SS have a poor prognosis leading to an interest in the development of new therapies with targeted mechanisms of action and acceptable safety profiles. In this review we focus on such novel strategies that have changed the treatment paradigm of this rare malignancy. BioMed Central 2012-05-17 /pmc/articles/PMC3418166/ /pubmed/22594538 http://dx.doi.org/10.1186/1756-8722-5-24 Text en Copyright ©2012 Jain et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Jain, Salvia
Zain, Jasmine
O’Connor, Owen
Novel therapeutic agents for cutaneous T-Cell lymphoma
title Novel therapeutic agents for cutaneous T-Cell lymphoma
title_full Novel therapeutic agents for cutaneous T-Cell lymphoma
title_fullStr Novel therapeutic agents for cutaneous T-Cell lymphoma
title_full_unstemmed Novel therapeutic agents for cutaneous T-Cell lymphoma
title_short Novel therapeutic agents for cutaneous T-Cell lymphoma
title_sort novel therapeutic agents for cutaneous t-cell lymphoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3418166/
https://www.ncbi.nlm.nih.gov/pubmed/22594538
http://dx.doi.org/10.1186/1756-8722-5-24
work_keys_str_mv AT jainsalvia noveltherapeuticagentsforcutaneoustcelllymphoma
AT zainjasmine noveltherapeuticagentsforcutaneoustcelllymphoma
AT oconnorowen noveltherapeuticagentsforcutaneoustcelllymphoma

Ejemplares similares